系统性AAV给药后的血栓性微血管病变依赖于抗囊抗体
Stephanie M Salabarria1, Manuela Corti1, Kirsten E Coleman1
1Department of Pediatrics, University of Florida, Gainesville, Florida, USA.
The Journal of clinical investigation
|November 21, 2023
概括
系统性腺相关病毒 (AAV) 基因疗法可能导致危险的炎症. 一项新的研究表明,Rituximab,Sirolimus和类固醇的联合治疗有效地预防了免疫激活和血栓性微血管病变 (TMA).
科学领域:
- 免疫学 免疫学 免疫学
- 基因治疗 基因治疗
- 毒理学 毒理学 毒理学
背景情况:
- 系统性腺相关病毒 (AAV) 管理可能导致严重的炎症反应.
- 这些反应包括血栓式微血管病变 (TMA),损伤,心肌炎症和肝毒性.
研究的目的:
- 为了研究系统性AAV9管理后的免疫激活动力学.
- 评估两种不同的预防性免疫调节方案,以预防AAV相关的不良事件.
主要方法:
- 研究了38名接受全身AAV9治疗的个人,两种疗法:单独使用皮质类固醇 (组1) 或皮质类固醇加 rituximab 和 sirolimus (组2).
- 监测免疫标记物,包括免疫球蛋白 (IgM,IgG),D-二次体,血小板计数和补充通路激活 (C4,C5b-9,Ba,Bb).
主要成果:
- 第1组显示IgM和IgG的迅速增加,表明TMA,并激活了古典和替代补充通路.
- 第二组在免疫球蛋白和补充激活方面表现出最小的变化.
- 在第一组中观察到TMA标记物,如D-二次数升高和血小板减少.
结论:
- 在AAV基因疗法中,血栓性微血管病变 (TMA) 是抗体依赖的,涉及经典补充通路.
- 替代补充途径放大了TMA的发展.
- 在全身基因疗法中确定了管理免疫媒介事件的关键干预措施.
相关概念视频
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Drug Binding to Blood Components
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...


